Session » Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1390

A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1374

A Deep Neural Network Classifier to Identify Inflammatory Systemic Sclerosis Patients from Histological Images

8:30AM-10:30AM: Abstract Number: 1384

A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1369

Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial

8:30AM-10:30AM: Abstract Number: 1377

Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies

8:30AM-10:30AM: Abstract Number: 1367

Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1364

Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment

8:30AM-10:30AM: Abstract Number: 1368

Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing

8:30AM-10:30AM: Abstract Number: 1381

Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1370

Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

8:30AM-10:30AM: Abstract Number: 1388

Heterogeneity of Primary and Secondary Peristalsis in Systemic Sclerosis: A New Model of Scleroderma Esophagus

8:30AM-10:30AM: Abstract Number: 1375

Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1387

Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1386

Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH

8:30AM-10:30AM: Abstract Number: 1376

Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review

8:30AM-10:30AM: Abstract Number: 1372

Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD

8:30AM-10:30AM: Abstract Number: 1385

Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study

8:30AM-10:30AM: Abstract Number: 1373

Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1383

Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model

8:30AM-10:30AM: Abstract Number: 1378

Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort

8:30AM-10:30AM: Abstract Number: 1380

Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study

8:30AM-10:30AM: Abstract Number: 1365

Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1379

Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1389

Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases

8:30AM-10:30AM: Abstract Number: 1382

Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 1371

Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches

8:30AM-10:30AM: Abstract Number: 1366

The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].